It also helps that Seqirus is moving toward what it deems a “differentiated and high value” flu vaccine portfolio, driven by its latest quadrivalent flu shots—Fluad Quad, Flucelvax Quad and ...

CSL Seqirus, a business of CSL (ASX: CSL), today announced that it has commenced shipping its differentiated portfolio of influenza vaccines. This year, the company's influenza vaccines are being ...

Seqirus advised of “some adverse events” for Flucelvax Quad recorded in children and adults during clinical trials. “But they were generally mild to moderate in nature,” the company said.

Flucelvax Quadrivalent: A Next-Generation Flu Vaccine Flucelvax Quadrivalent is an influenza vaccine developed and produced by Seqirus.

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based ...

New Seqirus flu shot for children to be developed at Holly Springs plant A new flu shot is FDA approved for kids as young as 6 months old. You might not know that the shot will be made in Wake County.

March 28, 2022 MONTREAL, March 28, 2022 /CNW/ -- Seqirus, a global leader in influenza prevention, announced today that it has received Health Canada approval of FLUCELVAX ® QUAD (Influenza ...

CSL’s new generation of influenza vaccine — dubbed its ‘super jab’ — has won regulatory approval for use on toddlers ahead of the winter cold season and amid record demand for its flu shots.